We took a long hard look at the psychedelics clinical trials furthest along in the regulatory pathway and put together an analysis of what we found. Latest from Catherine Schuster-Bruce & me: (1/11) businessinsider.com/psychedelics-c…

Here are some of the most influential regulators, advocates, and executives shaping the first ever regulated psilocybin market in the US. Latest from me & Catherine Schuster-Bruce: businessinsider.com/oregon-power-p…

Who is deciding what legal "magic" mushrooms in the US might look like? We looked to Oregon to find out. bit.ly/3O1UiL2 Yeji Jesse Lee | 이예지 Insider Healthcare

Who is creating a framework for Oregon's legalization of #psilocybin to happen? @Jesse_Yeji & Dr. @DrCatherineSB of @ThisIsInsider are naming a few: Myles Katz; @David_Bronner of Dr. Bronner's; Mason Marks, MD, JD; Kathryn Tucker, JD; @SherisEckert and more. businessinsider.com/oregon-power-p…

It might be the middle of July, but the healthcare team Business Insider has been busy this week putting out fascinating reads on the future of the industry. (thread!)

Well said theconversation.com/psychedelic-dr…

🧵#ScienceBreakdown: "Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors" Interesting new paper by Olson Lab, Lin Tian, PhD, et al. looking at why some serotonin 2A receptor agonists promote neuroplasticity, but others do not. 1/

We don't rely on press releases/statements: every few months Catherine Schuster-Bruce and I contact each company on our tracker & reach out to new ones to ask when we should expect more data, how their trials are faring, and how much $ they have on hand to continue backing their studies